Reshma Mahtani
About
Reshma Mahtani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Reshma Mahtani has authored 80 papers receiving a total of 630 indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 28 papers in Cancer Research. Recurrent topics in Reshma Mahtani's work include Advanced Breast Cancer Therapies (37 papers), Cancer Treatment and Pharmacology (27 papers) and HER2/EGFR in Cancer Research (26 papers). Reshma Mahtani is often cited by papers focused on Advanced Breast Cancer Therapies (37 papers), Cancer Treatment and Pharmacology (27 papers) and HER2/EGFR in Cancer Research (26 papers). Reshma Mahtani collaborates with scholars based in United States, United Kingdom and Germany. Reshma Mahtani's co-authors include Charles L. Vogel, Mohammad Jahanzeb, John S. Macdonald, Muaiad Kittaneh, Alberto J. Montero, Mark D. Pegram, Lee S. Schwartzberg, Elyse E. Lower, Nadia Harbeck and Eugene R. Ahn and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
In The Last Decade
Reshma Mahtani
73 papers receiving 620 citations
Peers
Reshma Mahtani
Neelima Vidula United States
Erica Stringer-Reasor United States
Patricia Gómez Spain
Rossella Martinello Italy
Akshara Singareeka Raghavendra United States
Maria Rosa Cappelletti Italy
Monica Milano Italy
Olga Martínez‐Sáez Spain
D. Ilegbodu United States
Christoph Uleer Germany
Citations per year, relative to Reshma Mahtani Reshma Mahtani (= 1×)
peers
Neelima Vidula
Countries citing papers authored by Reshma Mahtani
Since
Specialization
Citations
This map shows the geographic impact of Reshma Mahtani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reshma Mahtani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reshma Mahtani more than expected).
Fields of papers citing papers by Reshma Mahtani
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Reshma Mahtani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reshma Mahtani. The network helps show where Reshma Mahtani may publish in the future.
Co-authorship network of co-authors of Reshma Mahtani
This figure shows the co-authorship network connecting the top 25 collaborators of Reshma Mahtani. A scholar is included among the top collaborators of Reshma Mahtani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reshma Mahtani. Reshma Mahtani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mahtani, Reshma, et al.. (2025). Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Early Breast Cancer Treatment and Outcomes by Risk of Recurrence: A Retrospective US Electronic Health Records Study. Cancers. 17(11). 1848–1848.
2.
Ueno, Naoto T., Francesco Cottone, William Jacot, et al.. (2025). Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC. The Oncologist. 30(5).
3.
Mahtani, Reshma, et al.. (2024). Expanding treatment options for patients with HER2+ metastatic breast cancer with margetuximab plus chemotherapy: a case report series. Frontiers in Oncology. 14. 1419246–1419246.
4.
Huppert, Laura A., Reshma Mahtani, Naomi Dempsey, et al.. (2024). Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies.. Journal of Clinical Oncology. 42(16_suppl). 1083–1083.
5.
Jeselsohn, Rinath, Jingxin Fu, Reshma Mahtani, et al.. (2024). Abstract PS12-02: Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2- Metastatic Breast Cancer. Cancer Research. 84(9_Supplement). PS12–2.
6.
Jagsi, Reshma, William E. Barlow, Wendy A. Woodward, et al.. (2023). Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. JAMA Oncology. 9(8). 1083–1083.
7.
Bardhan, Mainak, Vinay Suresh, Vyshak Alva Venur, et al.. (2023). An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?. Expert Review of Neurotherapeutics. 24(1). 77–103.
8.
Lin, Nancy U., Virginia F. Borges, Manish R. Patel, et al.. (2023). 382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer. Annals of Oncology. 34. S338–S338.
9.
Bartsch, Rupert, Evandro de Azambuja, Erika Hamilton, et al.. (2022). Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. The Oncologist. 27(9). 722–731.
10.
Rugo, Hope S., Seock‐Ah Im, Anil A. Joy, et al.. (2022). Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3. The Breast. 66. 324–331.
11.
Kittaneh, Muaiad, Sunil Badve, Humberto Caldera, et al.. (2020). Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clinical Breast Cancer. 20(3). 183–193.
12.
Mahtani, Reshma, et al.. (2020). 312P Real-world (RW) multi-country study of BRCA1/2 mutation (BRCA1/2mut) testing trends among adult patients (pts) with HER2− advanced breast cancer (ABC). Annals of Oncology. 31. S367–S368.
13.
Lux, Michael P., et al.. (2020). 314P Real-world (RW) multi-country study of BRCA1/2 testing in adult patients (pts) with HER2−advanced breast cancer (ABC). Annals of Oncology. 31. S368–S369.
14.
Lewis, Katie, et al.. (2020). 327P Treatment sequencing in HR+/HER2- locally advanced or metastatic breast cancer: A real-world retrospective study in France, Germany, Italy and Spain. Annals of Oncology. 31. S375–S376.
15.
Ramdial, Jeremy, et al.. (2019). Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients. Breast Cancer Research and Treatment. 176(2). 253–260.
16.
Mahtani, Reshma, Sunil Badve, Humberto Caldera, et al.. (2019). A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clinical Breast Cancer. 20(3). e251–e260.
17.
Abraham, Jame, Humberto Caldera, Robert E. Coleman, et al.. (2018). Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Research and Treatment. 169(1). 1–7.
18.
Zeichner, Simon B., et al.. (2014). A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer. Breast Cancer Research and Treatment. 146(1). 7–14.
19.
Mahtani, Reshma & Mohammad Jahanzeb. (2010). Bisphosphonates as Anticancer Therapy for Early Breast Cancer. Clinical Breast Cancer. 10(5). 359–366.
20.
Mahtani, Reshma, Alisha Stein, & Charles L. Vogel. (2009). High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: A retrospective chart review. Clinical Therapeutics. 31. 2371–2378.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Neelima Vidula Breakdown of academic impact, for papers by Erica Stringer-Reasor Breakdown of academic impact, for papers by Patricia Gómez Breakdown of academic impact, for papers by Rossella Martinello Breakdown of academic impact, for papers by Akshara Singareeka Raghavendra Breakdown of academic impact, for papers by Maria Rosa Cappelletti Breakdown of academic impact, for papers by Monica Milano Breakdown of academic impact, for papers by Olga Martínez‐Sáez Breakdown of academic impact, for papers by D. Ilegbodu Breakdown of academic impact, for papers by Christoph Uleer